Scientific Vita
Publi­cations
Con­tact

Prof. Dr.

Mathias Heikenwälder

Academic Education and University Degrees

2009
Habilitation in Experimental Pathology, Medical Faculty, University Hospital Zürich, Switzerland, mentor Prof. Dr. Holger Moch
2004
Graduation as Dr. sc. nat. at the University of Zürich, Switzerland with a Ph.D
2001
Ph.D. thesis, Institute of Neuropathology, University Hospital Zürich (USZ), Switzerland (Grade: summa cum laude); supervised by Prof. Dr. Adriano Aguzzi
1999
Diploma thesis with the group of Prof. Dr. Martin Zenke, Max-Delbrück center for Molecular Medicine (MDC), Berlin, Germany
1994 - 1999
Studies of Microbiology and Genetics at the University of Vienna, Austria, the Max-Perutz laboratories, Vienna, and the Institute of Molecular Pathology (IMP), Vienna, Austria.

Employment

Since 10/2015
Research group leader Institute of Molecular Immunology and Experimental Oncology
Since 10/2015
W3-Professur „Infection and Cancer“, German Cancer Research Center Heidelberg and Medical Faculty, Heidelberg University, Germany
2012
W2-Professor, TU München and Research Associate at the University Hospital of Zürich, Clinical Pathology; Munich, Germany
2010
Helmholtz Young Investigator, Helmholtz-Zentrum München (HMGU), Germany
2010
Sponsor and leading investigator of a clinical trial at the clinical trial Center Zürich (CTC), University Hospital Zürich, Switzerland to treat HCV-genotype 1 infected patients, group leader at the Dep. of Pathology USZ.
2007
Prof. Dr. Max-Cloëtta fellow and independent group leader at the Department of Pathology and start as a principal investigator (PI), University of Zürich, Switzerland
2006
Staff scientist and lecturer in the Department of Pathology, Institute of Neuropathology, University of Zürich, Switzerland
2004
Postdoctoral fellow at the Institute of Neuropathology, Pathology Department, University Hospital Zürich (USZ), Switzerland.
Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M, Wohlleber D, Lorentzen A, Einer C, Schulz S, Clavel T, Protzer U, Thiele C, Zischka H, Moch H, Tschöp M, Tumanov A, Haller D, Unger K, Karin M, Kopf M, Knolle P°, Weber A°, Heikenwalder M°. 2014. Metabolic activation of intrahepatic CD8+ T-cells and NKT-cells causes nonalcoholic steatohepatitis and hepatocellular carcinoma via cross-talk with hepatocytes. Cancer Cell 26:549-64. &, co-corresponding authors
Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M°, Protzer U°. 2014. Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science 343:1221-8.
Kruglov AA, Grivennikov SI, Kuprash DV, Winsauer C, Prepens S, Seleznik GM, Eberl G, Littman DR, Heikenwalder M, Tumanov AV, Nedospasov SA. 2013. Nonredundant function of soluble LTα3 produced by innate lymphoid cells in intestinal homeostasis. Science 342:1243-6.
Huang LR, Wohlleber D, Reisinger F, Kurts C, Protzer U, Heikenwalder M°, Knolle PA°. 2013. Intrahepatic myeloid cell-aggregates enable local CD8+ T cell expansion and successful immunotherapy against chronic viral liver infection. Nature Immunology 14:574-83.
Seleznik GM, Reding T, Romrig F, Saito Y, Mildner A, Segerer S, Sun LK, Stephan Regenass S, Lech M, Anders HJ, McHugh D, Kumagi T, Hiasa Y, Lackner C, Haybaeck J, Angst E, Perren A, Balmer ML, Slack E, MacPherson A, Manz M, Weber A, Browning JL, Arkan MC, Rülicke T, Aguzzi A, Prinz M, Graf R°, Heikenwalder M°. 2012. Lymphotoxin αβ Receptor Signaling Promotes Development of Autoimmune Pancreatitis. Gastroenterology 143:1361-74.
Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M, Croner RS, Konrad A, Manz M, Moch H, Aguzzi A, Van Loo G, Pasparakis M, Prinz M, Borsig L°, Heikenwalder M°. 2012. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 22:91-105.
Krautler NJ, Kana V, Kranich J, Tian Y, Perera D, Lemm D, Schwarz P, Armulik A, Browning JL, Tallquist M, Buch T, Oliveira-Martins JB, Zhu C, Hermann M, Wagner U, Brink R, Heikenwalder M, Aguzzi A. 2012. Follicular dendritic cells emerge from ubiquitous perivascular precursors. Cell 150:194-206.
Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. 2010. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330:980-2.
Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, Müller M, de Vos R, Wolf MJ, Boege Y, Seleznik GM, Zeller N, Erny D, Fuchs T, Zoller S, Cairo S, Buendia MA, Prinz M, Akira S, Tacke F, Heikenwalder M, Trautwein C, Luedde T. 2010. TAK1 suppresses a NEMO-dependent, but NF-κB independent pathway to liver cancer. Cancer Cell 17:481-96.
Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M. 2009. A lymphotoxin- driven pathway to hepatocellular carcinoma. Cancer Cell 16:295-308. °Co-corresponding author - & Co-last author
Address
Institute of Molecular Immunology and Experimental Oncology
Klinikum München rechts der Isar,
Technische Universität München
Ismaningerstr. 22
81675 München
eMail
heikenwaelder@helmholtz-muenchen.de